Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.34 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.34 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.34 |
| ▸ | PTGFR | P43088 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethyl Sulfoxide SCHEMBL28215050 | 0.87 | KDM4E (0.42) | KDM4EALDH1A1HCAR2POLBSMN1; SMN2 | |
| SCHEMBL1403879 | 0.77 | ALDH1A1 (0.40) | KDM4EALDH1A1HCAR2POLBTSHR | |
| SCHEMBL1708233 | 0.77 | ALDH1A1 (0.40) | KDM4EALDH1A1HCAR2POLBSMN1; SMN2 | |
| SCHEMBL1855352 | 0.77 | KDM4E (0.40) | KDM4EALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL24787182 | 0.76 | CA12 (0.36) | KDM4EALDH1A1HCAR2POLBP4HA1 | |
| SCHEMBL3705899 | 0.76 | ALDH1A1 (0.54) | KDM4EALDH1A1HCAR2POLBTSHR | |
| Methane SCHEMBL26985795 | 0.75 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL31153429 | 0.74 | ALDH1A1 (0.39) | KDM4EALDH1A1HCAR2POLBSMN1; SMN2 | |
| SCHEMBL3695695 | 0.74 | GABRP (0.41) | KDM4EALDH1A1HCAR2POLBTSHR | |
| SCHEMBL20929049 | 0.74 | HCAR2 (0.34) | KDM4EALDH1A1HCAR2P4HA1P4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 532 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114702506-B | 11-carbonyl-20-ethoxy source oridonin and 14-OH esterified serial derivatives and application thereof | 郑州大学 | 2023-08-22 | — | — | CN | claimed |
| CN-114702506-A | 11-carbonyl-20-ethoxy economic oridonin and 14-OH esterified series derivatives and application thereof | 郑州大学 | 2022-07-05 | — | — | CN | claimed |
| EP-2456763-B1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | claimed |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-01-15 | — | — | US | claimed |
| CN-102471293-B | Oxazine derivatives and their use as BACE inhibitors for the treatment of neurological disorders | NOVARTIS AG (CH) | 2014-10-01 | — | — | CN | claimed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | claimed |
| EP-2663308-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | claimed |
| CN-102666507-A | Oxazine derivatives and their use in the treatment of neurological disorders | NOVARTIS AG | 2012-09-12 | — | — | CN | claimed |
| EP-2483255-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-08-08 | — | — | EP | claimed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | claimed |
| EP-2456763-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-05-30 | — | — | EP | claimed |
| CN-102471293-A | Oxazine derivatives and their use as BACE inhibitors for the treatment of neurological disorders | NOVARTIS AG | 2012-05-23 | — | — | CN | claimed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | claimed |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4695271-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | Merck Sharp & Dohme LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| US-20020147204-A1 | Amide derivative | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2002-10-10 | — | — | US | disclosed |
| US-6384033-B1 | DRUGS FOR VISION DEFECTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-05-07 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | KDM4E 3316/4885ALDH1A1 2685/4885HCAR2 1261/4885 |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | KDM4E 3346/4885ALDH1A1 1316/4885HCAR2 1611/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | KDM4E 627/4885ALDH1A1 1185/4885HCAR2 4035/4885 |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | MSR1, NR3C1, CCR1 | KDM4E 4270/4885ALDH1A1 868/4885HCAR2 87/4885 |
| US-20020147204-A1 | Amide derivative | ALDH1A2, NR1H2, HDAC3 | KDM4E 1808/4885ALDH1A1 202/4885HCAR2 57/4885 |
| US-20150018338-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | OTC, GRIK5, GRIN2C | KDM4E 3548/4885ALDH1A1 508/4885HCAR2 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.